Q-omics provides the consensus-scored CYCSP12 profile across patient tissues and cancer cell-line models. CYCSP12 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, CYCSP12 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, CYCSP12 RNA expression shows 5,972 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, KIRC, and STAD as cancer lineages where CYCSP12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCSP12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCSP12 survival associations across molecular data types. CYCSP12 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCSP12 RNA expression–survival associations across cancer types. High CYCSP12 expression shows unfavorable associations in ESCA, THCA, LIHC, LUAD and KIRC, but favorable associations in GBM. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for CYCSP12 RNA expression.
This table summarizes CYCSP12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CYCSP12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCSP12 shows lower tumor expression in KIRC. The KIRC box plot shows higher CYCSP12 RNA expression in normal versus tumor tissue (log2 FC = −0.018, t-test p = .040).
This table shows molecular features associated with CYCSP12 in patient tissues and cancer cell lines. In patient samples, CYCSP12 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
